Vikram Purohit
Stock Analyst at Morgan Stanley
(1.86)
# 3,266
Out of 5,143 analysts
162
Total ratings
35.94%
Success rate
-7.57%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Vikram Purohit
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| INCY Incyte | Maintains: Equal-Weight | $92 → $94 | $105.06 | -10.53% | 26 | Jan 6, 2026 | |
| CMPS COMPASS Pathways | Maintains: Overweight | $10 → $11 | $7.13 | +54.28% | 2 | Nov 5, 2025 | |
| ZBIO Zenas BioPharma | Maintains: Overweight | $31 → $34 | $20.40 | +66.67% | 3 | Oct 28, 2025 | |
| HALO Halozyme Therapeutics | Maintains: Overweight | $80 → $79 | $71.29 | +10.81% | 11 | Oct 20, 2025 | |
| ABSI Absci | Maintains: Overweight | $6.4 → $5.89 | $3.16 | +86.39% | 3 | Aug 18, 2025 | |
| RXRX Recursion Pharmaceuticals | Assumes: Equal-Weight | $5 | $4.96 | +0.81% | 4 | Jul 3, 2025 | |
| ASND Ascendis Pharma | Upgrades: Overweight | $180 → $250 | $228.65 | +9.34% | 19 | May 5, 2025 | |
| AXSM Axsome Therapeutics | Maintains: Overweight | $125 → $190 | $186.98 | +1.62% | 19 | Feb 27, 2025 | |
| FHTX Foghorn Therapeutics | Maintains: Equal-Weight | $6 → $9 | $6.20 | +45.16% | 9 | Sep 24, 2024 | |
| GMAB Genmab | Maintains: Equal-Weight | $31 | $33.10 | -6.34% | 2 | Sep 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $15 → $16 | $123.63 | -87.06% | 2 | Apr 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $45 → $10 | $26.65 | -62.48% | 8 | Nov 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $46 → $6 | $13.92 | -56.90% | 1 | Nov 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $43 → $42 | $15.98 | +162.83% | 8 | Aug 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $38 → $41 | $72.77 | -43.66% | 12 | Dec 19, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $120 → $40 | $7.06 | +466.57% | 7 | Dec 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Equal-Weight | $13 | $2.18 | +496.33% | 1 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $39 → $38 | $17.33 | +119.27% | 6 | Nov 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $24 → $20 | $10.11 | +97.82% | 5 | Aug 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $11 → $10 | $20.74 | -51.78% | 11 | Jul 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $22 | $1.18 | +1,764.41% | 1 | Aug 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $40 → $20 | $23.04 | -13.19% | 2 | Aug 5, 2020 |
Incyte
Jan 6, 2026
Maintains: Equal-Weight
Price Target: $92 → $94
Current: $105.06
Upside: -10.53%
COMPASS Pathways
Nov 5, 2025
Maintains: Overweight
Price Target: $10 → $11
Current: $7.13
Upside: +54.28%
Zenas BioPharma
Oct 28, 2025
Maintains: Overweight
Price Target: $31 → $34
Current: $20.40
Upside: +66.67%
Halozyme Therapeutics
Oct 20, 2025
Maintains: Overweight
Price Target: $80 → $79
Current: $71.29
Upside: +10.81%
Absci
Aug 18, 2025
Maintains: Overweight
Price Target: $6.4 → $5.89
Current: $3.16
Upside: +86.39%
Recursion Pharmaceuticals
Jul 3, 2025
Assumes: Equal-Weight
Price Target: $5
Current: $4.96
Upside: +0.81%
Ascendis Pharma
May 5, 2025
Upgrades: Overweight
Price Target: $180 → $250
Current: $228.65
Upside: +9.34%
Axsome Therapeutics
Feb 27, 2025
Maintains: Overweight
Price Target: $125 → $190
Current: $186.98
Upside: +1.62%
Foghorn Therapeutics
Sep 24, 2024
Maintains: Equal-Weight
Price Target: $6 → $9
Current: $6.20
Upside: +45.16%
Genmab
Sep 11, 2024
Maintains: Equal-Weight
Price Target: $31
Current: $33.10
Upside: -6.34%
Apr 11, 2024
Maintains: Equal-Weight
Price Target: $15 → $16
Current: $123.63
Upside: -87.06%
Nov 13, 2023
Maintains: Overweight
Price Target: $45 → $10
Current: $26.65
Upside: -62.48%
Nov 7, 2023
Downgrades: Equal-Weight
Price Target: $46 → $6
Current: $13.92
Upside: -56.90%
Aug 29, 2023
Maintains: Overweight
Price Target: $43 → $42
Current: $15.98
Upside: +162.83%
Dec 19, 2022
Maintains: Equal-Weight
Price Target: $38 → $41
Current: $72.77
Upside: -43.66%
Dec 12, 2022
Maintains: Equal-Weight
Price Target: $120 → $40
Current: $7.06
Upside: +466.57%
Nov 10, 2022
Initiates: Equal-Weight
Price Target: $13
Current: $2.18
Upside: +496.33%
Nov 4, 2022
Maintains: Equal-Weight
Price Target: $39 → $38
Current: $17.33
Upside: +119.27%
Aug 24, 2022
Maintains: Equal-Weight
Price Target: $24 → $20
Current: $10.11
Upside: +97.82%
Jul 25, 2022
Maintains: Underweight
Price Target: $11 → $10
Current: $20.74
Upside: -51.78%
Aug 10, 2021
Initiates: Overweight
Price Target: $22
Current: $1.18
Upside: +1,764.41%
Aug 5, 2020
Maintains: Equal-Weight
Price Target: $40 → $20
Current: $23.04
Upside: -13.19%